ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options
Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Tower Capital Asia announces majority investment in V-Key – a leader in digital identity and mobile application security
SINGAPORE, Feb. 12, 2026 /PRNewswire/ -- Tower Capital Asia ("TCA") is pleased…
Mitsubishi Electric and Landis+Gyr Accelerate Grid Edge Innovation as Mitsubishi Electric Takes Part in Landis+Gyr’s Application Ecosystem
ATLANTA and TOKYO, Jan. 27, 2026 /PRNewswire/ -- Mitsubishi Electric Corporation and…
FDA Accepts LEQEMBI IQLIK (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment…
SLK, an Altimetrik Company named Major Contender in Everest Group’s Application Transformation Services for AI-enablement PEAK Matrix Assessment 2025
BANGALORE, India, Dec. 24, 2025 /PRNewswire/ -- SLK, an Altimetrik Company has…
HKUST and SEMI Co-Host Inaugural 2025 Semiconductor Innovation and Intelligent Application Summit (SIIAS)
Uniting Global Semiconductor Leaders to Drive Industry Innovation and GrowthHONG KONG, Dec.…
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…
Alvotech Provides Update on the Status ofU.S. Biologics License Application for AVT05
REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a…
Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
